Innate Pharma
Clinical-stage biotech developing immunotherapies for cancer using the innate immune system.
IPH | PA
Overview
Corporate Details
- ISIN(s):
- FR0010331421 (+1 more)
- LEI:
- 9695002Y8420ZB8HJE29
- Country:
- France
- Address:
- 117 AVENUE DE LUMINY, 13009 MARSEILLE
- Website:
- http://www.innate-pharma.com/
- Sector:
- Manufacturing
Description
Innate Pharma is a clinical-stage, oncology-focused biotechnology company that develops immunotherapies for cancer patients. The company's scientific approach is centered on leveraging the innate immune system, particularly Natural Killer (NK) cells, to create novel treatments. Its innovative pipeline is composed of antibody-based therapeutics, including first-in-class monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific NK cell engagers based on its proprietary ANKET® platform. Key clinical programs include lacutamab (anti-KIR3DL2), monalizumab (anti-NKG2A) in partnership with AstraZeneca, and a portfolio of NK cell engagers targeting various hematological malignancies and solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2013-05-07 07:15 |
INNATE PHARMA ANNOUNCES 1Q2013 REVENUE AND CASH IN LINE WITH EXPECTATIONS
|
English | 30.0 KB | ||
| 2013-05-07 07:15 |
INNATE PHARMA ANNONCE SON CHIFFRE D'AFFAIRES ET SA TRÉSORERIE AU 31 MARS 2013,…
|
French | 30.3 KB | ||
| 2013-05-06 19:04 |
Rapport annuel et Document de référence 2012
|
French | 2.3 MB | ||
| 2013-04-12 07:15 |
INNATE PHARMA : Nouvelles données précliniques présentées sur les programmes pr…
|
French | 33.7 KB | ||
| 2013-04-12 07:15 |
INNATE PHARMA presents new data for proprietary programs targeting TLR3 and KIR…
|
English | 33.5 KB | ||
| 2013-03-05 07:15 |
ANNUAL RESULTS FOR 2012: SIGNIFICANT ADVANCE FOR FOUR DRUG CANDIDATES AND STRON…
|
English | 88.3 KB | ||
| 2013-03-05 07:15 |
RÉSULTATS 2012 : AVANCÉES IMPORTANTES DES QUATRE CANDIDAT-MÉDICAMENTS ET POSITI…
|
French | 89.0 KB | ||
| 2013-02-07 07:15 |
INNATE PHARMA (Euronext Paris: FR0010331421 - IPH) REPORTS INCREASE IN ANNUAL R…
|
English | 35.3 KB | ||
| 2013-02-07 07:15 |
INNATE PHARMA SA (Euronext Paris: FR0010331421 - IPH) ANNONCE DES PRODUITS OPÉR…
|
French | 37.0 KB | ||
| 2013-01-04 18:30 |
INNATE PHARMA : Full-year report on Innate Pharma's liquidity contract with Gil…
|
English | 37.0 KB | ||
| 2013-01-04 18:30 |
INNATE PHARMA : Bilan annuel du contrat de liquidité d'Innate Pharma à la Soci…
|
French | 29.0 KB | ||
| 2012-12-19 18:00 |
Innate Pharma annonce son calendrier financier pour 2013 ainsi que ses prochain…
|
French | 30.1 KB | ||
| 2012-12-19 18:00 |
Innate Pharma announces its financial calendar for 2013 and its participation t…
|
English | 30.2 KB | ||
| 2012-12-19 07:30 |
Innate Pharma : Phase I clinical trial of IPH2102/BMS-986015 in combination wit…
|
English | 38.5 KB | ||
| 2012-12-19 07:30 |
Innate Pharma : Annonce d'un essai clinique de Phase I avec IPH2102/BMS-986015 …
|
French | 40.0 KB |
Automate Your Workflow. Get a real-time feed of all Innate Pharma filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Innate Pharma
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Innate Pharma via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-01-10 | N/A | Other | Buy | 6,000 | N/A |
| 2024-01-02 | N/A | Other | Buy | 20,000 | N/A |
Peer Companies
